Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.

Oncotarget · 2016 · PMC4884932 · PMID 26862735

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There was also a trend towards an increase of VMAT-2 (VMAT2) mRNA expression; however, it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.